Calgary, AB – SemBioSys Genetics, a biotechnology company developing a broad pipeline of protein-based pharmaceutical and non-pharmaceutical products, today announced that it has received the company of the year award at the BIOTECanada Conference 2005 and annual general meeting in Toronto. The award recognizes a Canadian biotech company that has distinguished itself from its peers with strong overall performance, demonstrated leadership and a diverse product portfolio.
“BIOTECanada is rightly proud to represent a large family of Canadian biotechnology companies. It is an honour for SemBioSys to have been selected for this award. It demonstrates the commitment of our employees, directors, stakeholders and partners, and our progress toward building a leading biotech company,” said Andrew Baum, president and CEO of SemBioSys Genetics Inc. “This award recognizes our diverse pipeline of pharmaceutical products, insulin and a cardiovascular drug called Apo AI, and non-pharmaceutical products based on our ability to produce, extract and purify recombinant proteins.”